quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:13:50·44d
INSIDERFiling
Supernus Pharmaceuticals Inc. logo

President, CEO Khattar Jack A. converted options into 38,640 shares and covered exercise/tax liability with 16,574 shares, increasing direct ownership by 2% to 1,228,644 units (SEC Form 4)

SUPN· Supernus Pharmaceuticals Inc.
Health Care
Original source

Companies

  • SUPN
    Supernus Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Oct 9UpdatePiper Sandler$65.00
  • Jul 30UpdateCantor Fitzgerald$42.00
  • Feb 19UpdateCantor Fitzgerald$36.00
  • Jan 6UpdateCantor Fitzgerald$57.00
  • Sep 11UpdatePiper Sandler$36.00
  • Jan 3UpdateJefferies$45.00

Related

  • SEC1d
    Supernus Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR1d
    Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
  • PR3d
    Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig
  • SEC16d
    Supernus Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Supernus Pharmaceuticals Inc.
  • INSIDER36d
    SEC Form 4 filed by Supernus Pharmaceuticals Inc.
  • INSIDER38d
    President, CEO Khattar Jack A. acquired 12,500 shares, disposed of 12,500 shares and sold $1,763,124 worth of shares (35,000 units at $50.37), increasing direct ownership by 1% to 1,241,144 units (SEC Form 4)
  • INSIDER38d
    Director Hudson Frederick M. sold $271,725 worth of shares (5,369 units at $50.61), decreasing direct ownership by 8% to 60,413 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022